Caspofungin first-line therapy for invasive aspergillosis in allogeneic hematopoietic stem cell transplant patients: an European Organisation for Research and Treatment of Cancer study

Caspofungin at standard dose was evaluated as first-line monotherapy of mycologically documented probable/proven invasive aspergillosis (IA) (unmodified European Organisation for Research and Treatment of Cancer/Mycosis Study Group criteria) in allogeneic hematopoietic SCT patients. The primary effi...

Descripción completa

Detalles Bibliográficos
Autores: Herbrecht, R, Maertens, J, Baila, L, Aoun, M, Heinz, W, Martino, R, Schwartz, S, Ullmann, AJ, Meert, L, Paesmans, M, Marchetti, O, Akan, H, Ameye, L, Shivaprakash, M, Viscoli, C
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2010
País:España
Institución:Institut d’Investigació Biomèdica Sant Pau (IIB Sant Pau)
Repositorio:r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
OAI Identifier:oai:iibsantpau.fundanetsuite.com:p12654
Acceso en línea:https://iibsantpau.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=12654
Access Level:acceso abierto
Palabra clave:allogeneic
aspergillosis
caspofungin
hematopoietic SCT
id ES_bde7fe1d47047e30a01cc902b35ccc3d
oai_identifier_str oai:iibsantpau.fundanetsuite.com:p12654
network_acronym_str ES
network_name_str España
repository_id_str
spelling Caspofungin first-line therapy for invasive aspergillosis in allogeneic hematopoietic stem cell transplant patients: an European Organisation for Research and Treatment of Cancer studyHerbrecht, RMaertens, JBaila, LAoun, MHeinz, WMartino, RSchwartz, SUllmann, AJMeert, LPaesmans, MMarchetti, OAkan, HAmeye, LShivaprakash, MViscoli, Callogeneicaspergillosiscaspofunginhematopoietic SCTCaspofungin at standard dose was evaluated as first-line monotherapy of mycologically documented probable/proven invasive aspergillosis (IA) (unmodified European Organisation for Research and Treatment of Cancer/Mycosis Study Group criteria) in allogeneic hematopoietic SCT patients. The primary efficacy end point was complete or partial response at end of caspofungin treatment. Response at week 12, survival and safety were additional end points. Enrollment was stopped prematurely because of low accrual, with 42 enrolled and 24 eligible, giving the study a power of 85%. Transplant was from unrelated donors in 16 patients; acute or chronic GVHD was present in 15. In all, 12 patients were neutropenic (<500/mu l) at baseline, 10 received steroids and 16 calcineurin inhibitors or sirolimus. Median duration of caspofungin treatment was 24 days. At the end of caspofungin therapy, 10 (42%) patients had complete or partial response (95% confidence interval: 22-63%); 1 (4%) and 12 (50%) had stable and progressing disease, respectively; one was not evaluable. At week 12, eight patients (33%) had complete or partial response. Survival rates at week 6 and 12 were 79 and 50%, respectively. No patient had a drug-related serious adverse event or discontinued because of toxicity. Caspofungin first-line therapy was effective and well tolerated in allogeneic hematopoietic SCT patients with mycologically documented IA. Bone Marrow Transplantation (2010) 45, 1227-1233; doi: 10.1038/bmt.2009.334; published online 11 January 2010NATURE PUBLISHING GROUP2010info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttps://iibsantpau.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=12654BONE MARROW TRANSPLANTATIONISSN: 02683369ISSNe: 14765365reponame:r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pauinstname:Institut d’Investigació Biomèdica Sant Pau (IIB Sant Pau)Inglésinfo:eu-repo/semantics/openAccessoai:iibsantpau.fundanetsuite.com:p126542026-06-14T12:41:47Z
dc.title.none.fl_str_mv Caspofungin first-line therapy for invasive aspergillosis in allogeneic hematopoietic stem cell transplant patients: an European Organisation for Research and Treatment of Cancer study
title Caspofungin first-line therapy for invasive aspergillosis in allogeneic hematopoietic stem cell transplant patients: an European Organisation for Research and Treatment of Cancer study
spellingShingle Caspofungin first-line therapy for invasive aspergillosis in allogeneic hematopoietic stem cell transplant patients: an European Organisation for Research and Treatment of Cancer study
Herbrecht, R
allogeneic
aspergillosis
caspofungin
hematopoietic SCT
title_short Caspofungin first-line therapy for invasive aspergillosis in allogeneic hematopoietic stem cell transplant patients: an European Organisation for Research and Treatment of Cancer study
title_full Caspofungin first-line therapy for invasive aspergillosis in allogeneic hematopoietic stem cell transplant patients: an European Organisation for Research and Treatment of Cancer study
title_fullStr Caspofungin first-line therapy for invasive aspergillosis in allogeneic hematopoietic stem cell transplant patients: an European Organisation for Research and Treatment of Cancer study
title_full_unstemmed Caspofungin first-line therapy for invasive aspergillosis in allogeneic hematopoietic stem cell transplant patients: an European Organisation for Research and Treatment of Cancer study
title_sort Caspofungin first-line therapy for invasive aspergillosis in allogeneic hematopoietic stem cell transplant patients: an European Organisation for Research and Treatment of Cancer study
dc.creator.none.fl_str_mv Herbrecht, R
Maertens, J
Baila, L
Aoun, M
Heinz, W
Martino, R
Schwartz, S
Ullmann, AJ
Meert, L
Paesmans, M
Marchetti, O
Akan, H
Ameye, L
Shivaprakash, M
Viscoli, C
author Herbrecht, R
author_facet Herbrecht, R
Maertens, J
Baila, L
Aoun, M
Heinz, W
Martino, R
Schwartz, S
Ullmann, AJ
Meert, L
Paesmans, M
Marchetti, O
Akan, H
Ameye, L
Shivaprakash, M
Viscoli, C
author_role author
author2 Maertens, J
Baila, L
Aoun, M
Heinz, W
Martino, R
Schwartz, S
Ullmann, AJ
Meert, L
Paesmans, M
Marchetti, O
Akan, H
Ameye, L
Shivaprakash, M
Viscoli, C
author2_role author
author
author
author
author
author
author
author
author
author
author
author
author
author
dc.subject.none.fl_str_mv allogeneic
aspergillosis
caspofungin
hematopoietic SCT
topic allogeneic
aspergillosis
caspofungin
hematopoietic SCT
description Caspofungin at standard dose was evaluated as first-line monotherapy of mycologically documented probable/proven invasive aspergillosis (IA) (unmodified European Organisation for Research and Treatment of Cancer/Mycosis Study Group criteria) in allogeneic hematopoietic SCT patients. The primary efficacy end point was complete or partial response at end of caspofungin treatment. Response at week 12, survival and safety were additional end points. Enrollment was stopped prematurely because of low accrual, with 42 enrolled and 24 eligible, giving the study a power of 85%. Transplant was from unrelated donors in 16 patients; acute or chronic GVHD was present in 15. In all, 12 patients were neutropenic (<500/mu l) at baseline, 10 received steroids and 16 calcineurin inhibitors or sirolimus. Median duration of caspofungin treatment was 24 days. At the end of caspofungin therapy, 10 (42%) patients had complete or partial response (95% confidence interval: 22-63%); 1 (4%) and 12 (50%) had stable and progressing disease, respectively; one was not evaluable. At week 12, eight patients (33%) had complete or partial response. Survival rates at week 6 and 12 were 79 and 50%, respectively. No patient had a drug-related serious adverse event or discontinued because of toxicity. Caspofungin first-line therapy was effective and well tolerated in allogeneic hematopoietic SCT patients with mycologically documented IA. Bone Marrow Transplantation (2010) 45, 1227-1233; doi: 10.1038/bmt.2009.334; published online 11 January 2010
publishDate 2010
dc.date.none.fl_str_mv 2010
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv https://iibsantpau.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=12654
url https://iibsantpau.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=12654
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.publisher.none.fl_str_mv NATURE PUBLISHING GROUP
publisher.none.fl_str_mv NATURE PUBLISHING GROUP
dc.source.none.fl_str_mv BONE MARROW TRANSPLANTATION
ISSN: 02683369
ISSNe: 14765365
reponame:r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname:Institut d’Investigació Biomèdica Sant Pau (IIB Sant Pau)
instname_str Institut d’Investigació Biomèdica Sant Pau (IIB Sant Pau)
reponame_str r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
collection r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869418240836370432
score 15,812429

Similares en LA Referencia